OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia
Mohamed El‐Tanani, Hamdi Nsairat, Ismail Matalka, et al.
Pathology - Research and Practice (2024) Vol. 254, pp. 155161-155161
Open Access | Times Cited: 15
Mohamed El‐Tanani, Hamdi Nsairat, Ismail Matalka, et al.
Pathology - Research and Practice (2024) Vol. 254, pp. 155161-155161
Open Access | Times Cited: 15
Showing 15 citing articles:
Advancements of metallic nanoparticles: A promising frontier in cancer treatment
Ali Al‐Samydai, Maha N. Abu Hajleh, Farah Al-Sahlawi, et al.
Science Progress (2024) Vol. 107, Iss. 4
Open Access | Times Cited: 9
Ali Al‐Samydai, Maha N. Abu Hajleh, Farah Al-Sahlawi, et al.
Science Progress (2024) Vol. 107, Iss. 4
Open Access | Times Cited: 9
Atypical Femur Fracture in a Teenager on Chronic Imatinib Therapy
Ana C. Belzarena, James L. Cook
Case Reports in Oncological Medicine (2025) Vol. 2025, Iss. 1
Open Access | Times Cited: 1
Ana C. Belzarena, James L. Cook
Case Reports in Oncological Medicine (2025) Vol. 2025, Iss. 1
Open Access | Times Cited: 1
MDM2 inhibitors induce apoptosis by suppressing MDM2 and enhancing p53, Bax, Puma and Noxa expression levels in imatinib‑resistant chronic myeloid leukemia cells
Akihiro Kimura, Masanobu Tsubaki, Teruki Obana, et al.
Biomedical Reports (2025) Vol. 22, Iss. 4
Open Access | Times Cited: 1
Akihiro Kimura, Masanobu Tsubaki, Teruki Obana, et al.
Biomedical Reports (2025) Vol. 22, Iss. 4
Open Access | Times Cited: 1
Historical Perspective and Current Trends in Anticancer Drug Development
Katarzyna Gach, Joanna Drogosz-Stachowicz, Anna Janecka, et al.
Cancers (2024) Vol. 16, Iss. 10, pp. 1878-1878
Open Access | Times Cited: 6
Katarzyna Gach, Joanna Drogosz-Stachowicz, Anna Janecka, et al.
Cancers (2024) Vol. 16, Iss. 10, pp. 1878-1878
Open Access | Times Cited: 6
Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Journal of Molecular Biology (2025), pp. 169050-169050
Open Access
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Journal of Molecular Biology (2025), pp. 169050-169050
Open Access
Ferroptosis as the new approach to Cancer therapy
Oluwafemi Adeleke Ojo, Stephen R. Grant, Pearl Ifunanya Nwafor-Ezeh, et al.
Cancer Treatment and Research Communications (2025), pp. 100913-100913
Open Access
Oluwafemi Adeleke Ojo, Stephen R. Grant, Pearl Ifunanya Nwafor-Ezeh, et al.
Cancer Treatment and Research Communications (2025), pp. 100913-100913
Open Access
Advancing chronic myeloid leukemia research with next-generation sequencing: potential benefits, limitations, and future clinical integration
Henry Sutanto, Laras Pratiwi, Pradana Zaky Romadhon, et al.
Human Genetics (2025)
Closed Access
Henry Sutanto, Laras Pratiwi, Pradana Zaky Romadhon, et al.
Human Genetics (2025)
Closed Access
BCR-ABL: The Molecular Mastermind behind Chronic Myeloid Leukemia
Tara Shammas, Malalage N. Peiris, April N. Meyer, et al.
Cytokine & Growth Factor Reviews (2025)
Closed Access
Tara Shammas, Malalage N. Peiris, April N. Meyer, et al.
Cytokine & Growth Factor Reviews (2025)
Closed Access
Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia
Ayca Irgit, Reyhan Kamıs, Belgin Sever, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 5
Open Access
Ayca Irgit, Reyhan Kamıs, Belgin Sever, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 5
Open Access
Structure‐guided drug design targeting Abl kinase: how structure and regulation can assist in designing new drugs
Diego Martins, Philipe Oliveira Fernandes, Lucas A. Vieira, et al.
ChemBioChem (2024)
Closed Access | Times Cited: 2
Diego Martins, Philipe Oliveira Fernandes, Lucas A. Vieira, et al.
ChemBioChem (2024)
Closed Access | Times Cited: 2
Multi-Omics Integration for Liver Cancer Using Regression Analysis
Aditya Raj, Ruben C. Petreaca, Golrokh Mirzaei
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 4, pp. 3551-3562
Open Access | Times Cited: 1
Aditya Raj, Ruben C. Petreaca, Golrokh Mirzaei
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 4, pp. 3551-3562
Open Access | Times Cited: 1
N6-methyladenosine (m6A) RNA modification in chronic myeloid leukemia: unveiling a novel therapeutic target
Guillermo Fernandez Rodriguez, Marco Tarullo, Alessandro Fatica
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 1
Guillermo Fernandez Rodriguez, Marco Tarullo, Alessandro Fatica
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 1
Green synthesized Zingiber officinale -ZnO nanoparticles: anticancer efficacy against 3D breast cancer model
Ruqaya Alhaddad, Bassam M. Abualsoud, Ibrahim Al‐Deeb, et al.
Future Science OA (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Ruqaya Alhaddad, Bassam M. Abualsoud, Ibrahim Al‐Deeb, et al.
Future Science OA (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Targeting the Bcr-Abl Oncoprotein in Leukemia: Molecular Docking Analysis and Toxicity Prediction of Potential Therapeutic Candidates
Ivan Vito Ferrari
(2024)
Open Access
Ivan Vito Ferrari
(2024)
Open Access
Nanotechnology based approaches for leukemia therapy
Biomedical Letters (2024) Vol. 10, Iss. 2, pp. 90-103
Closed Access
Biomedical Letters (2024) Vol. 10, Iss. 2, pp. 90-103
Closed Access
